Medable Inc., a clinical development technology company, launched Medable AI, a suite of GenAI capabilities integrated into its Studio platform. The suite will be available from December 2024 and aims to streamline digital and decentralized clinical trials for sponsors and research organizations.

The AI suite features automated eCOA creation that converts existing outcome assessments into a digital format, a ChatGPT-like interface for editing assessments, and scalable assessment-generation capabilities. According to early metrics, the suite can complete multiple outcome assessments in 30 minutes, typically taking days.

The company claims the new AI capabilities will reduce the time to First Patient In (FPI), streamline workflows, and provide users greater transparency and control over trial builds. Medable plans to expand these AI capabilities across its platform in the future.

Analyst QuickTake: This is Medable's second new offering this year. Earlier, in August , the company launched Medable Studio, an all-in-one application for configuring, translating, validating, and launching electronic clinical outcome assessment (eCOA) Plus solutions (which include eCOA, e-consent, televisions , and sensors) into clinical trials. With Medable AI's launch, the company is potentially looking to expand its market share through internal product innovation.